Information for Technology Transfer Offices.

A critical aspect throughout this Challenge is respect for the intellectual property rights of investigators, institutions and GSK. Consultation with an institution’s Technology Transfer Office (TTO) is essential to confirm that initial applications do not contain undisclosed subject matter that may be patentable. Because of this, we require that investigators who apply to the 2018 Discovery Fast Track Australian Challenge notify their institution’s TTO prior to submitting an application.

Challenge Terms and Conditions

The application requires that investigators:

  1. Waive any claims of confidentiality to the initial application, and hence, agree that GSK shall be free to use the application for informational purposes for evaluating potential winners as outlined in the Challenge Terms and Conditions

  2. Agree that only non-confidential information has been disclosed, and agree that they have received endorsement from the appropriate persons/groups/departments at their institution (including the TTO) to submit the application.

    The application will not progress unless the investigator agrees to both of the above listed statements.

TTO review of submitted 2018 Discovery Fast Track Australian Challenge applications for their institution

When an application is submitted, an institution’s TTO staff member is required to provide approval via email for each application in order to allow our GSK judges to start their review. Until this email confirmation is received from an institution’s TTO, our GSK judges will be unable to view the investigator's application. To enable this TTO review, all investigators who apply to the Challenge will be required to include the email address of a staff member within their institution’s TTO on the application. Upon the investigator submitting the application, the TTO staff member will receive an email informing them that an application has been submitted and that it requires TTO email confirmation before our GSK judges can review it. The TTO staff member will be requested to review the application(s) by following a link via the 2018 Discovery Fast Track Australian Challenge portal and then respond via email to to provide confirmation.

Once the approval email confirmation is received, our GSK judges start their review. TTOs are encouraged to provide an approval email confirmation within five business days from the date we alert the TTO of the application submission or to deny approval and request that the application is withdrawn from the Challenge. The final deadline for TTO approval confirmation is 4 May, 2018 (five business days after the close of registration). If the TTO approval is not confirmed by this date, GSK will withdraw the application from the Challenge. If an institution’s TTO wishes to provide a blanket approval of all applications so that the TTO staff member is not required to provide this additional approval confirmation for each application after submission, they must write to us via and formally make this request. Even in the case of blanket approvals, TTO staff members will receive an email notification when an application is submitted and will be encouraged to create an account in order to view applications submitted by investigators affiliated with their institution.

Create an account

In the first instance, the TTO staff member will be informed about how to create an account in the 2018 Discovery Fast Track Australian Challenge portal. They will then send an email to to have their online account designated as an “officer” account for their institution. Once we have activated this request, the TTO staff member will be notified via email and can access the portal to view applications from their institution. The TTO staff member can choose not to create an account and arrange with the investigator to review the application outside of the 2018 Discovery Fast Track Australian Challenge portal. If this is the case, they still need to respond via email to confirm that our GSK judges have permission to start their review.

Challenge Confidentiality Disclosure Agreement (CDA) for finalists

If selected as a finalist of the Challenge, the investigator, in consultation with the institution’s TTO, will be requested to enter into a Challenge Confidential Disclosure Agreement (CDA). The CDA will be signed between the institution and GSK, with the finalist acknowledging and agreeing to the terms of the CDA. A CDA is intended for use when confidential information is being shared between two parties and is not appropriate when only non-confidential information is being shared.

Challenge Material Transfer Agreement (MTA) for winners

Once selected, finalists and their respective TTOs will be asked to initiate discussions to confirm that the institution can execute the Challenge Material Transfer Agreement (MTA). This early action will enable sufficient time for the institution to review and understand the MTA before winners are selected. Once winners are selected, our offer to screen their target is conditional upon execution of the Challenge MTA by the winner’s institution. Please note that the MTA will be an agreement between the institution and GSK, with the investigator signing the MTA to acknowledge agreement to its provisions. The purpose of the MTA is to facilitate the transfer of biological reagents to GSK to enable high throughput and/or ELT screening. The MTA also governs next steps that may result from the screening process, including the potential sharing of structures for tool compounds from GSK to the institution, and protects the IP rights of both parties.

Possible research outcomes

For winning investigators and their respective institutions, this compound discovery effort could lead to a longer-term drug discovery collaboration through a Discovery Partnerships with Academia (DPAc) collaboration.

Once the screen and follow up experiments are complete, four research outcomes are possible:

Outcome One: The screening results are positive and both GSK and the institution wish to collaborate.

As per the terms of the Challenge Material Transfer Agreement (MTA), GSK and the institution can negotiate a full DPAc agreement with potential further research funding toward the development of a new medicine.

If the parties cannot reach agreement on a DPAc deal, then GSK can elect outcome three as defined in the Challenge MTA.

Outcome Two: The screening results are positive, but GSK chooses not to proceed with further collaboration

Outcome Two: The screening results are positive, but GSK chooses not to proceed with further collaboration

As per the terms of the Challenge Material Transfer Agreement (MTA), GSK will, at its sole discretion, either (i) provide up to 3 compound structures from the Research to the institution, or (ii) together, GSK and the institution will publish compound structures from the Research.

Outcome Three: GSK desires to enter into a DPAc agreement with the institution, but the institution declines to proceed.

As per the terms of the Challenge Material Transfer Agreement (MTA), if the investigator does not want to continue the relationship, but GSK desires to continue the research, then GSK would be free to proceed with an internal program and no structures of any compound from the Research would be revealed to the investigator and institution. If the program was successful, GSK would pay the institution pre-clinical and clinical milestone payments (as agreed between GSK and the institution).

Outcome Four: Neither GSK nor the investigator/institution wants to enter into a full DPAc agreement or the screen does not provide useful compounds.

As per the terms of the Challenge Material Transfer Agreement (MTA), if the results of the screen are such that the institution and GSK agree there is little value in continuing the relationship and so the relationship ends, GSK will not have an obligation to provide to the institution or to publish any structures of any compound from the Research.